Literature DB >> 17121490

Targeting of B cells in SLE: rationale and therapeutic opportunities.

Gregg J Silverman1.   

Abstract

B cells were first implicated in lupus pathogenesis because of their roles as autoantibody producers. B cells, which play important roles in (auto)immune recognition, are now understood to also have other functional capabilities that contribute to the recruitment and stimulation of T lymphocytes and cells of the innate immune system. Herein, these emerging insights are discussed as well as the newly recognized influence on B cells of the Toll-like receptors, which are postulated to be important sources of costimulation for autoreactive B cells. Also discussed is how B-cell survival factors may contribute to the loss of immune tolerance that leads to pathologic autoimmunity. These findings are part of the rationale for the development of new specific B-cell-targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17121490

Source DB:  PubMed          Journal:  Bull NYU Hosp Jt Dis        ISSN: 1936-9719


  4 in total

Review 1.  B cell modulation in rheumatology.

Authors:  Gregg J Silverman; Sahil Khanna
Journal:  Curr Opin Pharmacol       Date:  2007-07-10       Impact factor: 5.547

2.  Inhibition of the catalytic function of activation-induced cytidine deaminase promotes apoptosis of germinal center B cells in BXD2 mice.

Authors:  Hui-Chen Hsu; Pingar Yang; Qi Wu; John H Wang; Godwin Job; Tanja Guentert; Jun Li; Cecil R Stockard; Thuc-Vy L Le; David D Chaplin; William E Grizzle; John D Mountz
Journal:  Arthritis Rheum       Date:  2011-07

3.  Rituximab therapy for juvenile-onset systemic lupus erythematosus.

Authors:  Obioma Nwobi; Carolyn L Abitbol; Jayanthi Chandar; Wacharee Seeherunvong; Gastón Zilleruelo
Journal:  Pediatr Nephrol       Date:  2007-12-19       Impact factor: 3.714

Review 4.  The Homophilic Domain - An Immunological Archetype.

Authors:  Heinz Kohler; Jagadeesh Bayry; Srinivas V Kaveri
Journal:  Front Immunol       Date:  2016-03-21       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.